- Home
- WRLD vs GERN Comparison
WRLD vs GERN Comparison
Compare WRLD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- GERN
- Stock Information
- Founded
- WRLD 1962
- GERN 1990
- Country
- WRLD United States
- GERN United States
- Employees
- WRLD N/A
- GERN N/A
- Industry
- WRLD Finance: Consumer Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- GERN Health Care
- Exchange
- WRLD Nasdaq
- GERN Nasdaq
- Market Cap
- WRLD 859.5M
- GERN 823.0M
- IPO Year
- WRLD 1991
- GERN 1996
- Fundamental
- Price
- WRLD $176.63
- GERN $1.27
- Analyst Decision
- WRLD
- GERN Buy
- Analyst Count
- WRLD 0
- GERN 7
- Target Price
- WRLD N/A
- GERN $3.17
- AVG Volume (30 Days)
- WRLD 44.4K
- GERN 6.8M
- Earning Date
- WRLD 10-24-2025
- GERN 11-06-2025
- Dividend Yield
- WRLD N/A
- GERN N/A
- EPS Growth
- WRLD 10.95
- GERN N/A
- EPS
- WRLD 14.92
- GERN N/A
- Revenue
- WRLD $567,706,032.00
- GERN $164,447,000.00
- Revenue This Year
- WRLD N/A
- GERN $175.15
- Revenue Next Year
- WRLD $3.55
- GERN $56.61
- P/E Ratio
- WRLD $11.95
- GERN N/A
- Revenue Growth
- WRLD 0.80
- GERN 11877.20
- 52 Week Low
- WRLD $104.99
- GERN $1.09
- 52 Week High
- WRLD $185.48
- GERN $4.50
- Technical
- Relative Strength Index (RSI)
- WRLD 53.78
- GERN 42.83
- Support Level
- WRLD $165.96
- GERN $1.23
- Resistance Level
- WRLD $179.60
- GERN $1.48
- Average True Range (ATR)
- WRLD 5.42
- GERN 0.07
- MACD
- WRLD -0.12
- GERN -0.00
- Stochastic Oscillator
- WRLD 47.86
- GERN 6.82
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.